SciSparc to Acquire Xylo’s MUSE Endoscopic Device Portfolio for 19.99% Equity Stake

Reuters01-13

SciSparc to Acquire Xylo’s MUSE Endoscopic Device Portfolio for 19.99% Equity Stake

SciSparc Ltd. has signed a definitive agreement to acquire a portfolio of patents, trademarks, and intellectual property associated primarily with the MUSE™ endoscopic system from Xylo Technologies Ltd. The MUSE™ system is a single-use, innovative device designed for transoral fundoplication, a minimally invasive procedure to treat gastroesophageal reflux disease (GERD). As consideration for the acquired assets, SciSparc will issue to Xylo ordinary shares representing 19.99% of its issued and outstanding share capital as of the closing date, set for March 8, 2026, or may elect to issue pre-funded warrants in lieu of shares. SciSparc plans to begin commercializing the technologies immediately after closing, aiming to replicate Xylo's successful licensing model in Greater China by pursuing exclusive partnerships with regional distributors in North America, Europe, and Latin America. The transaction is subject to customary closing conditions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Scisparc Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9624676-en) on January 13, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2603744685?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-13 19:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603744685","market":"nz","top_or_hot":-1,"title":"SciSparc to Acquire Xylo’s MUSE Endoscopic Device Portfolio for 19.99% Equity Stake","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      SciSparc to Acquire Xylo’s MUSE Endoscopic Device Portfolio for 19.99% Equity Stake\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/SPRC\">SciSparc Ltd.</a> has signed a definitive agreement to acquire a portfolio of patents, trademarks, and intellectual property associated primarily with the MUSE™ endoscopic system from <a href=\"https://laohu8.com/S/XYLO\">Xylo Technologies</a> Ltd. The MUSE™ system is a single-use, innovative device designed for transoral fundoplication, a minimally invasive procedure to treat gastroesophageal reflux disease (GERD). As consideration for the acquired assets, SciSparc will issue to Xylo ordinary shares representing 19.99% of its issued and outstanding share capital as of the closing date, set for March 8, 2026, or may elect to issue pre-funded warrants in lieu of shares. SciSparc plans to begin commercializing the technologies immediately after closing, aiming to replicate Xylo's successful licensing model in Greater China by pursuing exclusive partnerships with regional distributors in North America, Europe, and Latin America. The transaction is subject to customary closing conditions.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Scisparc Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9624676-en) on January 13, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SciSparc to Acquire Xylo’s MUSE Endoscopic Device Portfolio for 19.99% Equity Stake</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSciSparc to Acquire Xylo’s MUSE Endoscopic Device Portfolio for 19.99% Equity Stake\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-13 19:55</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      SciSparc to Acquire Xylo’s MUSE Endoscopic Device Portfolio for 19.99% Equity Stake\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/SPRC\">SciSparc Ltd.</a> has signed a definitive agreement to acquire a portfolio of patents, trademarks, and intellectual property associated primarily with the MUSE™ endoscopic system from <a href=\"https://laohu8.com/S/XYLO\">Xylo Technologies</a> Ltd. The MUSE™ system is a single-use, innovative device designed for transoral fundoplication, a minimally invasive procedure to treat gastroesophageal reflux disease (GERD). As consideration for the acquired assets, SciSparc will issue to Xylo ordinary shares representing 19.99% of its issued and outstanding share capital as of the closing date, set for March 8, 2026, or may elect to issue pre-funded warrants in lieu of shares. SciSparc plans to begin commercializing the technologies immediately after closing, aiming to replicate Xylo's successful licensing model in Greater China by pursuing exclusive partnerships with regional distributors in North America, Europe, and Latin America. The transaction is subject to customary closing conditions.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Scisparc Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9624676-en) on January 13, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0314104364.USD","symbol_name":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nNDLb237cL:1","article_id":"2603744685","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2603744685","pubTimestamp":1768305310,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"SciSparc Ltd. has signed a definitive agreement to acquire a portfolio of patents, trademarks, and intellectual property associated primarily with the MUSE endoscopic system from Xylo Technologies Ltd. The MUSE system is a single-use, innovative device designed for transoral fundoplication, a minimally invasive procedure to treat gastroesophageal reflux disease . As consideration for the acquired assets, SciSparc will issue to Xylo ordinary shares representing 19.99% of its issued and outstanding share capital as of the closing date, set for March 8, 2026, or may elect to issue pre-funded warrants in lieu of shares. SciSparc plans to begin commercializing the technologies immediately after closing, aiming to replicate Xylo's successful licensing model in Greater China by pursuing exclusive partnerships with regional distributors in North America, Europe, and Latin America. The transaction is subject to customary closing conditions.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","SPRC":"SciSparc Ltd.","BK4588":"碎股","BK4112":"金融交易所和数据","NDAQ":"纳斯达克OMX交易所","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","BK4007":"制药","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","BK4585":"ETF&股票定投概念","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK4139":"生物科技"},"translate_title":"SciSparc将以19.99%股权收购Xylo的MUSE内窥镜设备组合","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SPRC":0.9,"NDAQ":0.9},"content_text":"SciSparc to Acquire Xylo’s MUSE Endoscopic Device Portfolio for 19.99% Equity Stake\n    \n\nSciSparc Ltd. has signed a definitive agreement to acquire a portfolio of patents, trademarks, and intellectual property associated primarily with the MUSE™ endoscopic system from Xylo Technologies Ltd. The MUSE™ system is a single-use, innovative device designed for transoral fundoplication, a minimally invasive procedure to treat gastroesophageal reflux disease (GERD). As consideration for the acquired assets, SciSparc will issue to Xylo ordinary shares representing 19.99% of its issued and outstanding share capital as of the closing date, set for March 8, 2026, or may elect to issue pre-funded warrants in lieu of shares. SciSparc plans to begin commercializing the technologies immediately after closing, aiming to replicate Xylo's successful licensing model in Greater China by pursuing exclusive partnerships with regional distributors in North America, Europe, and Latin America. The transaction is subject to customary closing conditions.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Scisparc Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9624676-en) on January 13, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2603744685","isCrawlerRequest":true}